中文名稱:賴諾普利二水合物 | 英文名稱:Lisinopril dihydrate |
CAS:83915-83-7 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 99.87% | 產(chǎn)品類別: 抑制劑 |
貨號: T0706 |
名稱 | Lisinopril dihydrate |
描述 | Lisinopril dihydrate (MK-521) is an orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. |
體外活性 | Lisinopril significantly reduces left ventricular (LV) end-diastolic pressure (EDP), pulmonary capillary wedge pressure (PCWP) and end-diastolic stress, addition of atenolol to Lisinopril further reduces EDP and PCWP. [1] Lisinopril is a structural homologue of enalaprilat, differing only in the second amino acid side chain. Lisinopril inhibits Angiotensin-converting enzyme (ACE) in vitro, as well as after parenteral and oral administration to humans; its oral bioavailability is only 25-29%, but it has a longer duration of action than enalapril. [2] |
體內(nèi)活性 | Lisinopril treated SHR rats has significantly raised total cholesterol levels compared to untreated spontaneously hypertensive rats (SHR) rats (+27%), but not compared to lisinopril treated Wistar Kyoto rats (WKY) rats. [3] Lisinopril is a long-acting angiotensin-converting enzyme inhibitor which blocks the renin-angiotensin system (RAS) and reduces systemic blood pressure in rats. Lisinopril reduces the hydroxyproline level and inhibits accumulation of collagens in the pulmonary tissue of the treatment group (paraquat + lisinopril) and per-treatment group (lisinopril + paraquat) in rats. [4] Lisinopril results in preserved ultrafiltration volume (UF), glucose reabsorption (D 1 /D 0 glucose) and peritoneal thickness in rats. [5] Lisinopril (0.2 mg/kg twice a day for 10 days) protects the cell membrane integrity and lessens free radical-induced oxidant stress in guinea pig hearts. [6] |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | H2O : 10 mM DMSO : Insoluble |
關(guān)鍵字 | Inhibitor | inhibit | MK521 | Lisinopril dihydrate | Angiotensin-converting Enzyme (ACE) | MK-521 dihydrate | MK-521 | Lisinopril Dihydrate | MK 521 |
相關(guān)產(chǎn)品 | Benzocaine | Flurbiprofen | Sacubitril/Valsartan | Losartan | Captopril | Clarithromycin | Ramipril | Tranilast | Irbesartan | Losartan potassium | Cholesterol | Prednisone |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | FDA 上市藥物庫 | 膜蛋白靶向化合物庫 | 神經(jīng)退行性疾病化合物庫 | 藥物功能重定位化合物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.2651萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 化學(xué)試劑,生物活性小分子 | 經(jīng)營模式 | 貿(mào)易,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP1年
|
山東強森化工有限公司
|
2025-01-23 | |
詢價 |
VIP12年
|
深圳振強生物技術(shù)有限公司
|
2025-01-23 | |
¥4000 |
VIP12年
|
湖北威德利化學(xué)科技有限公司
|
2025-01-23 | |
詢價 |
VIP5年
|
武漢鼎信通藥業(yè)有限公司
|
2025-01-23 | |
¥800 |
VIP9年
|
武漢維斯?fàn)柭锕こ逃邢薰?/div>
|
2025-01-23 | |
詢價 |
VIP6年
|
湖北威德利化學(xué)試劑有限公司
|
2025-01-23 | |
詢價 |
VIP6年
|
武漢鼎信通藥業(yè)有限公司
|
2025-01-23 | |
詢價 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-23 | |
¥585 |
VIP4年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-23 | |
¥2650 |
VIP3年
|
湖北魏氏化學(xué)試劑股份有限公司
|
2025-01-22 |